This was the stock's fourth consecutive day of gains.

CVS Health's forward-looking guidance for 2025 offers a glimpse into management's expectations and potential recovery pathways. The company projects adjusted EPS for the full year 2025 to fall ...

CVS Health Corporation CVS posted adjusted earnings per share (EPS) of $2.25 in the first quarter of 2025, up 71.8% year over year. The metric also topped the Zacks Consensus Estimate by 34.7%.

CVS Health Corporation CVS posted adjusted earnings per share (EPS) of $2.25 in the first quarter of 2025, up 71.8% year over year. The metric also topped the Zacks Consensus Estimate by 34.7%. The ...

CVS provided initial 2025 adjusted EPS guidance in the range of $5.75 to $6.00. This reflects expected improvements in Aetna's Medicare Advantage margins and a multi-year $2 billion cost ...

CVS Health (NYSE:CVS), a leading integrated healthcare ... The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by 30.8%.

CVS Health reported Q4 sales of $97.71B, surpassing the $97.19B consensus, while adjusted EPS fell to $1.19 from $2.12, missing estimates. Health Services revenue dropped 4.3% to $47.02B ...

The analyst from Baird justified the new price target by applying a 9.0x price-to-earnings (P/E) multiple to the estimated 2025 earnings per share (EPS) of $5.68. This multiple aligns with CVS's ...

CVS Health revised its full-year 2024 adjusted EPS guidance to a range of $6.40 to $6.65, down from its previous forecast of at least $7.00 and below the analyst consensus of $6.97. The company ...